Beijing Hotgen Biotech Co Ltd (688068) – aksjekurser og nyheter

Hotgen Biotech, often simply referred to as Hotgen, is a Chinese biological technology company founded in 2005. It focuses on the manufacture of in-vitro diagnostic instruments and reagents. In September 2019, the company was listed on the Shanghai Stock Exchange. During the novel coronavirus pandemic, it specialized in making 2019-nCoV antigen diagnostic products, which obtained EU CE certification. Hotgen was formerly a constituent of the STAR 50 Index. Headquartered in Beijing, it also established presences in foreign markets, such as the United Kingdom, France, and Germany. The net profit of the company in 2021 exceeded 2.3 billion yuan, an increase of more than sixteen times from the previous year. In 2022, its RAT kits were distributed free of charge by the Hong Kong Government to the public. In November 2023, it attended the MEDICA Trade Fair in Düsseldorf. Wikipedia

Om Beijing Hotgen Biotech Co Ltd

Administrerende direktør-

Ansatte1,04k

Grunnlagt23. juni 2005

Hovedkontor-

Sektor-

Nettstedhotgen.com.cn

Alle verdier i CNY	sep. 2025	des. 2025	mars 2026	juni 2026
Inntekt	105,80 mill.	95,17 mill.	116,03 mill.	151,72 mill.
Varekostnad	49,91 mill.	40,31 mill.	55,11 mill.	36,50 mill.
Direkte driftskostnader	49,91 mill.	40,31 mill.	55,11 mill.	36,50 mill.
Utgifter til forskning og utvikling	19,65 mill.	94,81 mill.	49,10 mill.	46,03 mill.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	83,78 mill.	99,31 mill.	97,60 mill.	127,34 mill.
Driftskostnader	98,59 mill.	204,82 mill.	143,51 mill.	186,68 mill.
Totale driftskostnader	148,50 mill.	245,13 mill.	198,62 mill.	223,17 mill.
Driftsinntekter	−42,70 mill.	−149,96 mill.	−82,59 mill.	−71,46 mill.
Andre ikke-operasjonelle inntekter	−273,76k	2,19 mill.	−2,39 mill.	2,09 mill.
EBT inkludert uvanlige elementer	−20,92 mill.	−155,14 mill.	−82,67 mill.	−76,94 mill.
EBT uten uvanlige elementer	−28,82 mill.	−122,01 mill.	−69,59 mill.	−76,99 mill.
Kostnad for inntektsskatt	4,59 mill.	−6,98 mill.	−5,78k	−796,34k
Faktisk avgiftssats	−21,96 %	4,50 %	0,01 %	1,03 %
Andre driftskostnader	−5,37 mill.	6,99 mill.	−2,96 mill.	3,17 mill.
Nettoinntekt	−24,96 mill.	−107,09 mill.	−68,06 mill.	−58,07 mill.
Netto fortjenestemargin	−23,59 %	−112,52 %	−58,66 %	−38,27 %
Resultat per aksje	-	-	-	-
Rente- og investeringsinntekter	14,98 mill.	35,99 mill.	15,44 mill.	3,94 mill.
Rentekostnader	−289,66k	−7,96 mill.	−46,88k	−7,63 mill.
Netto rentekostnader	14,69 mill.	28,03 mill.	15,39 mill.	−3,69 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	−21,62 mill.	−129,90 mill.	−62,53 mill.	−53,46 mill.
Gevinst eller tap ved salg av eiendeler	601,43k	−579,43k	-	6,83k

Finance

Spør om hva som helst